Study guide

18.3 Epidemiology Measures & Population Health

NBME Comprehensive Basic Science Examination CBSE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Navigation

1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness

2 Human Development

2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care

3 Blood & Hematologic Disease

3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms

4 Immune System

4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology

5 Nervous System Anatomy & Disease

5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms

6 Behavioral Health

6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science

7 Musculoskeletal System

7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders

8 Skin & Soft Tissue

8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection

9 Cardiovascular Pathophysiology

9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension

10 Cardiovascular Pharmacology

10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs

11 Respiratory System

11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology

12 Renal Physiology & Electrolytes

12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation

13 Renal Pathology

13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease

14 Gastrointestinal System

14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption

15 Endocrine System

15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome

16 Reproductive System

16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia

17 Multisystem Processes & Disorders

17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology

18 Biostatistics & Epidemiology

18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health

19 Social Sciences & Communication

19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning

20 Integrated Disciplines Capstone

20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution

18.3 Epidemiology Measures & Population Health

Key Takeaways Explain This Topic AI

Incidence = new cases / population at risk / time (flow); prevalence = existing cases / population (stock); prevalence ≈ incidence × duration when steady state holds.

Mortality rates, case fatality, and attack rates answer different questions; attack rate is cumulative incidence in an outbreak-defined population.

Herd immunity threshold for a perfectly mixed population approximates 1 − 1/R0; outbreak investigation follows verify → define/count → describe (time/place/person) → hypothesize → test → control → communicate.

Primary prevention prevents disease onset; secondary detects early disease; tertiary reduces complications of established disease; risk factors are attributes increasing disease probability, while determinants of health include broader social/structural drivers.

p < α (often 0.05) addresses Type I error under a null, not clinical importance; power = 1 − β controls Type II error; confidence intervals estimate precision of effect sizes and whether null values are excluded.

Last updated: August 2026

18.3 Epidemiology Measures & Population Health

Quick Answer: Incidence = new cases over time; prevalence = existing cases at a time (≈ I × duration). Attack rate = ill / exposed in an outbreak. Herd immunity threshold ≈ 1 − 1/R0. Primary/secondary/tertiary prevention map to before disease / early detection / limit disability. p-values ≠ effect size; power = 1 − β; CIs show precision and null exclusion.

This section ties classical epidemiology measures to prevention, outbreak response, disparities framing, and the inferential statistics tested alongside biostats on CBSE/PBLI-style items.

Incidence vs Prevalence

Measure Definition Units / form Rises when…

Incidence (cumulative) New cases / population at risk over a period Dimensionless proportion over time window More new disease

Incidence rate (density) New cases / person-time at risk Cases per person-year More new disease or better ascertainment

Prevalence (point) Existing cases / population at a time Proportion Higher incidence or longer duration (better survival, chronicity)

Relationship (steady state, low disease): Prevalence ≈ incidence × average duration.

Worked example 1 — Incidence and prevalence

City of 100,000 with no disease at t = 0. Over 1 year, 500 new cases of a chronic condition develop; none die or leave; all remain diseased.

  • Annual cumulative incidence ≈ 500/100,000 = 0.5%
  • End-of-year prevalence ≈ 500/100,000 = 0.5% (first year)

If average duration becomes 10 years with steady 500 new cases/year, prevalence approaches 500 × 10 / 100,000 = 5% . Improved treatment that prolongs life with disease increases prevalence even if incidence is flat—classic exam trap.

Worked example 2 — Person-time rate

200 patients followed: 50 for 1 year, 100 for 2 years, 50 for 4 years without the event until 12 events occur.

  • Person-years = 50·1 + 100·2 + 50·4 = 50 + 200 + 200 = 450
  • Incidence rate = 12/450 = 0.0267 per person-year (≈ 2.67 per 100 person-years)
  • Mortality Rates and Related Metrics
  • Metric Formula (teaching form) Use
  • Crude mortality rate Deaths / mid-year population / time Overall death burden
  • Cause-specific mortality Deaths from cause / population / time Burden of one disease
  • Age-specific mortality Deaths in age band / population in band Compare age groups
  • Case fatality rate (CFR) Deaths from disease / cases of disease Severity among the ill
  • Proportionate mortality Deaths from cause / all deaths Share of deaths, not risk

CFR ≠ cause-specific mortality. CFR uses cases in the denominator; mortality uses population .

Worked example 3 — CFR vs mortality

Population 1,000,000; 2,000 myocardial infarctions; 400 MI deaths in a year.

  • CFR = 400/2000 = 20%
  • Cause-specific MI mortality = 400/1,000,000 = 0.04% per year (40 per 100,000)
  • Attack Rate

Attack rate is cumulative incidence in a clearly defined exposed group during an outbreak window:

Attack rate = number who became ill / number exposed (at risk)

Often expressed as percent. Food-specific attack rates compare foods at a picnic.

Worked example 4 — Outbreak table

  • Ate potato salad Ill Well Total Attack rate
  • Yes 45 15 60 45/60 = 75%
  • No 10 40 50 10/50 = 20%

Risk ratio = 0.75/0.20 = 3.75 . Potato salad is the leading hypothesis for the vehicle. Secondary attack rate among household contacts uses new cases among contacts / susceptible contacts.

Herd Immunity Threshold (Concept)

Basic reproduction number R0 = average secondary cases from one infectious person in a fully susceptible population.

Effective reproduction number Rt falls as immunity rises.

With homogeneous mixing and solid immunity, herd immunity threshold (HIT):

  • HIT ≈ 1 − 1/R0
  • Worked example 5

If R0 = 5, HIT ≈ 1 − 1/5 = 0.80 (80%) immune needed so each case produces <1 secondary case on average.

If R0 = 15 (highly transmissible agent), HIT ≈ 93% .

Imperfect vaccines require higher coverage: roughly HIT / vaccine effectiveness.

Real populations are not perfectly mixed; clustering and waning immunity complicate estimates—but the formula is standard exam material.

Outbreak Investigation Steps

A practical sequence (order may overlap):

Prepare / verify diagnosis — confirm the disease is real (lab, clinical criteria); rule out pseudo-outbreaks.

Confirm outbreak — cases exceed expected baseline.

Case definition — person, place, time, clinical/lab criteria (possible/probable/confirmed).

Find and count cases — active surveillance, line list.

Descriptive epidemiology — time (epidemic curve), place (spot map), person (age, sex, exposures).

Generate hypotheses — source, mode, vehicle, risk factors.

Test hypotheses — analytic epidemiology (cohort/case-control attack rates), environmental/lab testing.

Implement control and prevention — remove source, isolate, vaccinate, educate— often start control before all analytics finish when risk is high.

Communicate findings — public, clinicians, agencies.

Maintain surveillance — ensure outbreak ends; evaluate response.

Epidemic curve shapes: point source (single peak), continuous common source (prolonged plateau), propagated (serial peaks at incubation intervals).

Levels of Prevention

  • Level Goal Examples
  • Primary Prevent disease onset Immunization, smoking never-start, seat belts, clean water, PrEP

Secondary Detect early / preclinical disease to improve outcomes Pap smear, mammography, BP screening, newborn metabolic screen

Tertiary Reduce complications/disability of established disease Cardiac rehab post-MI, glycemic control to prevent retinopathy, stroke rehabilitation

Primordial prevention (sometimes tested) targets underlying social/environmental conditions that give rise to risk factors (e.g., urban design reducing default sedentary life).

Exam trap: treating severe disease complications is tertiary, not primary—even if heroic.

Risk Factors vs Determinants of Health

Risk factor: measurable attribute/exposure associated with increased probability of disease (hypertension → stroke; smoking → lung cancer). May be causal or marker.

Determinants of health: broader set of personal, social, economic, and environmental factors that influence health status—income, education, housing, racism/discrimination, access to care, built environment, health behaviors, genetics.

Health disparities (basic-science framing on CBSE): systematic, potentially avoidable differences in health outcomes between groups defined by social advantage. Mechanisms taught at the interface of biology and environment include chronic stress physiology (HPA/sympathetic activation), differential toxic exposures, nutrition access, infectious exposure density, and unequal treatment access—not "biological race as destiny." Disparities questions often ask which intervention level or structural factor best explains a gradient after individual risk factors are listed.

Statistical Significance vs Clinical Significance

  • Concept Meaning
  • Null hypothesis (H0) Usually "no association / no difference"

p-value Probability of data as extreme as observed if H0 true (with model assumptions); not P(H0 true), not effect size

  • α (Type I error rate) Prespecified false-positive threshold (commonly 0.05)
  • Statistically significant p < α (by convention)—may be tiny and meaningless clinically if n is huge
  • Clinical significance Effect size large enough to matter to patients/clinicians (ARR, NNT, QoL)
  • Worked example 6 — Significant but trivial

Drug lowers systolic BP by 0.5 mm Hg ; n = 100,000; p = 0.001. Statistically significant, clinically negligible for individuals. Conversely, a 15 mm Hg drop in a small pilot with p = 0.08 may be clinically promising but not "significant" at α = 0.05—need more power, not dismissal of the effect size.

Type I Error, Type II Error, and Power

  • H0 true H0 false
  • Reject H0 Type I error (false positive), probability α Correct detection (power)
  • Fail to reject H0 Correct Type II error (false negative), probability β

Power = 1 − β = probability of detecting a true effect of a specified size.

Power rises with: larger effect size, larger sample size, higher α, lower variance, more precise measurements, one-sided tests (when appropriate).

Worked example 7 — Interpreting β

Study designed with 80% power (β = 0.20) at α = 0.05 to detect ARR of 5%. If the true ARR is 5%, there is still a 20% chance of a nonsignificant result. A negative underpowered study does not prove no effect.

Confidence Intervals

A 95% confidence interval (CI) for a mean difference or RR is a range from a procedure that, in repeated sampling, covers the true parameter 95% of the time (frequentist teaching). Practical exam uses:

Width → precision (narrower = more precise, often larger n )

Whether null is inside → for difference, null is 0; for ratio, null is 1. If 95% CI for RR is 0.6–0.9, excludes 1 → consistent with statistical significance at α = 0.05 (two-sided) under standard correspondence

Clinical bounds → even if CI excludes null, if entire CI is within a trivial effect range, clinical importance remains doubtful

Worked example 8 — CI reading

RR = 1.20; 95% CI 0.95–1.52 → not statistically significant at 0.05; compatible with modest harm, null, or modest benefit— imprecise .

RR = 0.70; 95% CI 0.65–0.76 → precise protective association; still check absolute risks for decision-making.

Integration for CBSE Vignettes

Chronic disease more prevalent despite flat incidence → longer duration/survival .

Outbreak picnic → attack rates by food; highest AR and AR ratio drive hypothesis.

"What percent must be immune?" → 1 − 1/R0 .

Vaccine before exposure → primary prevention; mammography → secondary ; post-stroke rehab → tertiary .

Tiny p with tiny ARR → emphasize clinical vs statistical significance.

Nonsignificant trial with n = 20 → suspect low power , not proof of equivalence.

RR 0.5 (0.4–0.6) → significant and relatively precise; still compute NNT when rates given.

Population measures describe burden and spread; prevention levels organize interventions; inferential statistics police how we claim knowledge. Together they complete the 4–6% biostats/epidemiology band on the CBSE.